Company / Capital Expenditures
AGIOS PHARMACEUTICALS, INC. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$4.3M
FY2025
5-year range
$999.0K / $14.1M
FY2021-FY2025
Trend
+156.1%
vs FY2024
Sector context
#79 of 194
Health Care
What the data says
At $4M, AGIOS PHARMACEUTICALS, INC.'s capital expenditures ranks #79 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $999,000 in FY2023 to $14M in FY2022.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of -9.2%.
Improved from $999,000 to $4M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -32.6%
- 5-Year CAGR
- -9.2%
- 10-Year CAGR
- -
Sector benchmark
#79 of 194 in Health CareTop 41% of 194This company $4.3M Sector average $117.5M
▼
-96.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -9.2%, indicating a declining trend.
- In FY2025, capital expenditures increased 156.1% year-over-year.
- Ranks #79 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.83 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.3M | +156.1% |
| FY2024 | $1.7M | +68.7% |
| FY2023 | $999.0K | -92.9% |
| FY2022 | $14.1M | +145.7% |
| FY2021 | $5.7M | -17.8% |
| FY2020 | $7.0M | -41.9% |
| FY2019 | $12.0M | +21.3% |
| FY2018 | $9.9M | +114.3% |
| FY2017 | $4.6M | -53.3% |
| FY2016 | $9.9M | +666.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026